bevacizumab is an Outlook Therapeutics, Inc. program in neovascular Age-related Macular Degeneration. Its next catalyst is a Readout in Dec 2027. 4 FDA decisions on record below. Every date links its source.
All upcoming FDA decision dates on the 2026 PDUFA calendar
bevacizumab is marketed as LYTENAVA (bevacizumab-vikg); the events below include those tracked under the brand name. FDA approval tracked on pdufa.bio: neovascular Age-related Macular Degeneration (approved Jul 24, 2026). Earlier approvals may not be listed here; the FDA label is the full record. Sponsor: Outlook Therapeutics, Inc. (OTLK). Market-cap tier at the time we tracked it: Micro. We track 5 catalyst events for this program: 1 upcoming and 4 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
| Fund | Shares | Value at quarter end | Filing |
|---|---|---|---|
| Perceptive Advisors | 3,139,216 | $5.0 million | filed August 14, 2026 |
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
The next tracked catalyst for bevacizumab is a Readout in Dec 2027.
On Jul 24, 2026 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.
In our records bevacizumab is FDA-approved for neovascular Age-related Macular Degeneration (approved Jul 24, 2026). Other approved uses may not be tracked here; the FDA label is the full record.
Outlook Therapeutics, Inc. (OTLK).
Yes. The FDA approved an application for bevacizumab on Jul 24, 2026; the decision page linked above carries the source.
FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.